Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $173.25.
Several analysts have commented on ASND shares. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. Wedbush boosted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They set a “buy” rating and a $150.00 target price on the stock. Citigroup boosted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th.
View Our Latest Report on ASND
Institutional Investors Weigh In On Ascendis Pharma A/S
Ascendis Pharma A/S Stock Down 0.6 %
ASND opened at $145.23 on Tuesday. The business has a 50 day moving average price of $149.10 and a two-hundred day moving average price of $123.28. The company has a market cap of $8.46 billion, a PE ratio of -15.70 and a beta of 0.50. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating the consensus estimate of ($2.15) by $0.49. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.18 EPS for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
See Also
- Five stocks we like better than Ascendis Pharma A/S
- How to Start Investing in Real Estate
- The Charles Schwab Company Can Hit New Highs
- What is Put Option Volume?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- 3 Small Caps With Big Return Potential
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.